c-FOS Expression in Metastatic Basal Cell Carcinoma with Spontaneous Basosquamous Transition
DOI:
https://doi.org/10.2340/actadv.v103.5347Abstract
Abstract is missing (Short communication)
Downloads
References
Tan CZ, Rieger KE, Sarin KY. Basosquamous Carcinoma: Controversy, Advances, and Future Directions. Dermatol Surg 2017; 43: 23-31.
https://doi.org/10.1097/DSS.0000000000000815 DOI: https://doi.org/10.1097/DSS.0000000000000815
Saez E, Rutberg SE, Mueller E, Oppenheim H, Smoluk J, Yuspa SH, et al. c-fos is required for malignant progression of skin tumors. Cell 1995; 82: 721-732.
https://doi.org/10.1016/0092-8674(95)90469-7 DOI: https://doi.org/10.1016/0092-8674(95)90469-7
Fan H, Oro AE, Scott MP, Khavari PA. Induction of basal cell carcinoma features in transgenic human skin expressing Sonic Hedgehog. Nat Med 1997; 3: 788-792.
https://doi.org/10.1038/nm0797-788 DOI: https://doi.org/10.1038/nm0797-788
Oro AE, Higgins KM, Hu Z, Bonifas JM, Epstein EH, Jr., Scott MP. Basal cell carcinomas in mice overexpressing sonic hedgehog. Science 1997; 276: 817-821.
https://doi.org/10.1126/science.276.5313.817 DOI: https://doi.org/10.1126/science.276.5313.817
Briso EM, Guinea-Viniegra J, Bakiri L, Rogon Z, Petzelbauer P, Eils R, et al. Inflammation-mediated skin tumorigenesis induced by epidermal c-Fos. Genes Dev 2013; 27: 1959-1973.
https://doi.org/10.1101/gad.223339.113 DOI: https://doi.org/10.1101/gad.223339.113
Kuonen F, Li NY, Haensel D, Patel T, Gaddam S, Yerly L, et al. c-FOS drives reversible basal to squamous cell carcinoma transition. Cell Rep 2021; 37: 109774.
https://doi.org/10.1016/j.celrep.2021.109774 DOI: https://doi.org/10.1016/j.celrep.2021.109774
Bhutani T, Abrouk M, Sima CS, Sadetsky N, Hou J, Caro I, et al. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib. J Am Acad Dermatol 2017; 77: 713-718.
https://doi.org/10.1016/j.jaad.2017.03.038 DOI: https://doi.org/10.1016/j.jaad.2017.03.038
Zhao X, Ponomaryov T, Ornell KJ, Zhou P, Dabral SK, Pak E, et al. RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors. Cancer Res 2015; 75: 3623-3635.
https://doi.org/10.1158/0008-5472.CAN-14-2999-T DOI: https://doi.org/10.1158/0008-5472.CAN-14-2999-T
Zhao R, Wang B, Lowe L, Dlugosz A, Bichakjian CK. Metastatic same-site squamous cell carcinoma arising during vismodegib therapy for basal cell carcinoma. JAAD Case Rep 2022; 28: 54-57.
https://doi.org/10.1016/j.jdcr.2022.07.032 DOI: https://doi.org/10.1016/j.jdcr.2022.07.032
Cameron MC, Lee E, Hibler BP, Barker CA, Mori S, Cordova M, et al. Basal cell carcinoma: Epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. J Am Acad Dermatol 2019; 80: 303-317.
https://doi.org/10.1016/j.jaad.2018.03.060 DOI: https://doi.org/10.1016/j.jaad.2018.03.060
Peterson SC, Eberl M, Vagnozzi AN, Belkadi A, Veniaminova NA, Verhaegen ME, et al. Basal cell carcinoma preferentially arises from stem cells within hair follicle and mechanosensory niches. Cell Stem Cell 2015; 16: 400-412.
https://doi.org/10.1016/j.stem.2015.02.006 DOI: https://doi.org/10.1016/j.stem.2015.02.006
Lapouge G, Youssef KK, Vokaer B, Achouri Y, Michaux C, Sotiropoulou PA, et al. Identifying the cellular origin of squamous skin tumors. Proc Natl Acad Sci U S A 2011; 108: 7431-7436.
https://doi.org/10.1073/pnas.1012720108 DOI: https://doi.org/10.1073/pnas.1012720108
Youssef KK, Van Keymeulen A, Lapouge G, Beck B, Michaux C, Achouri Y, et al. Identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell Biol 2010; 12: 299-305.
https://doi.org/10.1038/ncb2031 DOI: https://doi.org/10.1038/ncb2031
Kilgour JM, Shah A, Eichstadt S, Bailey I, Aasi SZ, Sarin KY. Treatment of Cutaneous Squamous Cell Carcinoma With the Topical Histone Deacetylase Inhibitor Remetinostat. JAMA dermatology 2022; 158: 105-107.
https://doi.org/10.1001/jamadermatol.2021.4549 DOI: https://doi.org/10.1001/jamadermatol.2021.4549
ilgour JM, Shah A, Urman NM, Eichstadt S, Do HN, Bailey I, et al. Phase II open-label, single-arm trial to investigate the efficacy and safety of topical remetinostat gel in patients with basal cell carcinoma. Clin Cancer Res 2021; 27: 4717-4725.
https://doi.org/10.1158/1078-0432.CCR-21-0560 DOI: https://doi.org/10.1158/1078-0432.CCR-21-0560
Published
How to Cite
License
Copyright (c) 2023 Yu Kurokami, Yosuke Ishitsuka, Eiji Kiyohara, Atsushi Tanemura, Manabu Fujimoto
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
